- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
RPID
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Rapid Micro Biosystems Inc · Healthcare · Medical Devices
Latest close
1.99 USD
-3.9%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -27.0% below the Trend Line and sits at 10.1% of its 52-week range. The latest completed week returned -3.9%, after a 17.1% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: earnings are due in 13d.
Setup score
37
out of 100
Latest Close
1.99 USD
24 Jul 2026
1W Return
-3.9%
latest completed week
4W Return
17.1%
short-term follow-through
12W Return
-21.3%
quarterly tape
Trend Breadth
48.1%
25 of 52 weeks active
Volume Ratio
1.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.9%
Latest completed week; four-week move 17.1%.
Indicator stack
26/65
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
57 relevant articles in the latest sentiment read.
Event risk
13d
Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -27.0% below the Trend Line and sits at 10.1% of its 52-week range. The latest completed week returned -3.9%, after a 17.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.4x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.06
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 17.1% over four weeks, -21.3% over 12 weeks, and -51.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.29Latest activity-pressure read.
Pressure change129.0%Four-week change in activity pressure.
Leadership-39.34Latest relative-leadership reading.
RS change25.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value22/100Relative valuation strength. Underlying universe rank 79; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum5/100Medium-term price momentum. Underlying universe rank 96; rank 1 is best.
Growth76/100Revenue and earnings growth. Underlying universe rank 25; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 2.9x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -33.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 12.4% Gross profit retained from each unit of revenue.
- Operating margin
- -140.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -105.1% Free cash flow generated from revenue.
- Return on invested capital
- -119.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 16.0% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.5% Net share repurchases relative to market value.
- Shareholder yield
- -0.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity17 / 3
17 acquisitions and 3 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment52/100
Weighted news tone is neutral across 57 relevant articles.
8 positive · 46 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-59.7%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher10 of 2615 weeks finished lower.
Best week+19.2%Week of 10 Jul.
Worst week-31.3%Week of 13 Mar.
Latest week-3.9%Week of 24 Jul.
Shape of recent returns
Strong gains5
Modest gains5
Flat weeks1
Modest losses7
Sharp losses8
Recent vol9.3%13-week weekly-return volatility.
Base vol12.3%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew9.6% / -8.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank5 / 100
Group average-3.4%
Trend breadth34.0%
Trend34.0%active weekly trend signals
MD65.0%positive activity pressure
RS20.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape32/100
Trend, activity pressure, participation, and risk combine to a 32/100 tape read.
Indicator analysis12/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.02; No reversal markers Factors7/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 76; Small Cap Core rank 80 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 57 relevant articles.
Rapid Micro Biosystems Inc (RPID) Income Statement Insiders17 / 317 acquisitions and 3 disposals in the latest 180-day insider tape.
Earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 1.99 USD | -3.9% | 2.72 USD | 1.96 USD | 0.29 | -39.34 | 1.3M | Off |
| 17 Jul 2026 | 2.07 USD | 1.0% | 2.76 USD | 1.95 USD | 0.09 | -38.97 | 1.3M | Off |
| 10 Jul 2026 | 2.05 USD | 19.2% | 2.79 USD | 1.94 USD | -0.34 | -42.77 | 1.6M | Off |
| 3 Jul 2026 | 1.72 USD | 1.2% | 2.85 USD | 1.94 USD | -0.81 | -51.73 | 640.8K | Off |
| 26 Jun 2026 | 1.70 USD | -0.6% | 2.92 USD | 1.93 USD | -0.99 | -52.63 | 1.1M | Off |
| 19 Jun 2026 | 1.71 USD | -2.8% | 3.00 USD | 1.93 USD | -1.22 | -55.20 | 767.7K | Off |
| 12 Jun 2026 | 1.76 USD | -11.6% | 3.09 USD | 1.92 USD | -1.19 | -53.36 | 559.9K | Off |
| 5 Jun 2026 | 1.99 USD | -1.0% | 3.17 USD | 1.92 USD | -1.15 | -46.89 | 601.1K | Off |
| 29 May 2026 | 2.01 USD | -2.0% | 3.21 USD | 1.91 USD | -1.13 | -49.53 | 584.3K | Off |
| 22 May 2026 | 2.05 USD | -1.0% | 3.24 USD | 1.90 USD | -1.12 | -47.72 | 1.2M | Off |
| 15 May 2026 | 2.07 USD | -21.3% | 3.27 USD | 1.90 USD | -1.15 | -47.24 | 915.4K | Off |
| 8 May 2026 | 2.63 USD | 4.0% | 3.30 USD | 1.89 USD | -1.12 | -33.93 | 437.0K | Off |
| 1 May 2026 | 2.53 USD | 11.0% | 3.32 USD | 1.88 USD | -1.14 | -33.55 | 556.9K | Off |
| 24 Apr 2026 | 2.28 USD | 0.0% | 3.36 USD | 1.87 USD | -1.14 | -39.41 | 1.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.